US-based Agena Bioscience has received US Food and Drug Administration (FDA) premarket clearance for the IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System.

Agena said that IMPACT Dx combined function system will also be available in the European Union (EU).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is carried out on the system and is indicated for use as an aid in diagnosing patients with suspected thrombophilia. The test is intended for in vitro diagnostic use in a clinical laboratory setting.

Factor V Leiden mutation increases risk of venous thromboembolism seven-fold to 80-fold.

The company said that individuals heterozygous for the Factor II prothrombin mutation have 25% higher plasma prothrombin levels than individuals with wild type genotype, and a 2.8-fold increased risk of venous thromboembolism.

See Also:

Agena Bioscience chairman and interim CEO John Lillig said: "The clearance of our IMPACT Dx Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx System is a tremendous achievement that we believe contributes significant value to our business and represents the transition of our proven research-use-only MassARRAY System into the clinical diagnostics arena."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The IMPACT Dx Factor V Leiden and Factor II Genotyping Test is carried out using the IMPACT Dx System, which uses matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry to interrogate nucleic acids.

The IMPACT Dx System is designed for use with FDA-cleared or approved tests citing its use.